Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.
Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.
Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.
Oncolytics Biotech Inc. (NASDAQ: ONCY) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 5:25 pm ET. Dr. Matt Coffey, President & CEO, will present, with a live webcast available on the company’s Investor Relations page. The conference runs from May 18-20, 2021, featuring one-on-one investor meetings. Oncolytics is developing pelareorep, an immuno-oncolytic virus aimed at treating various cancers, including in combination with checkpoint inhibitors. For more details, visit Oncolytics' website.
Oncolytics Biotech announced the voting results from its Annual General Meeting held on May 7, 2021, with 41.41% of shares represented. All seven nominated directors were elected, receiving significant support: Deborah M. Brown (82.43%), Matthew C. Coffey (79.86%), and others exceeding 79% approval. Shareholders also approved resolutions relating to the number of directors and auditor appointments. Oncolytics continues to develop pelareorep for cancer treatment, highlighting ongoing clinical trials and strategic plans for a phase 3 registration study in metastatic breast cancer.
Oncolytics Biotech (NASDAQ: ONCY) reported solid clinical progress and financial results for Q1 2021. Key highlights include the successful achievement of primary endpoints in the AWARE-1 trial and strong preclinical data supporting pelareorep's synergy with various immunotherapeutic agents, including CAR T therapies. With over $50 million in cash, the company expects a cash runway through Q4 2022. The Phase 2 BRACELET-1 trial remains on track for full enrollment in Q4 2021, supporting the potential for enhanced breast cancer treatments.
Oncolytics Biotech (NASDAQ: ONCY) announces its upcoming 2021 Annual General Meeting, scheduled for May 7, 2021, at 12:00 p.m. ET. The meeting will be held virtually to ensure the safety of employees and shareholders. Shareholders are encouraged to vote by proxy before the May 5 deadline. Following the meeting, Oncolytics will provide a corporate update and discuss its first quarter 2021 financial results. The event will be accessible online. For detailed instructions on attending and voting, participants can refer to the company's Management Information Circular.
Oncolytics Biotech announced the acceptance of an abstract for its pancreatic adenocarcinoma trial at the 2021 ASCO Annual Meeting, scheduled virtually from June 4-8, 2021. The abstract, titled Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma, will be presented as an electronic poster.
Publication of the abstract will occur on May 19, 2021, while the poster will be available on June 4, 2021. Oncolytics continues to develop pelareorep, targeting various cancers and preparing for a phase 3 trial in metastatic breast cancer.
Oncolytics Biotech announced successful results from the AWARE-1 breast cancer study, achieving its primary endpoint. The study demonstrated that pelareorep, combined with the PD-L1 inhibitor atezolizumab, significantly enhances anti-cancer immune responses in HR+/HER2- patients. Key findings include a 60% increase in CelTIL score in cohort 2, indicating improved tumor immune activity. Management highlights the results as validation of their clinical strategy, paving the way for future registrational studies. The data underscores pelareorep's potential to boost checkpoint inhibitor efficacy in breast cancer treatments.
Oncolytics Biotech Inc. (NASDAQ: ONCY) announced promising preclinical data demonstrating that pelareorep can enhance the effectiveness of established anti-cancer agents, talazoparib and palbociclib. These findings were showcased at the AACR Annual Meeting 2021, where both combinations showed increased cancer cell apoptosis and improved tumor responses in murine models. Pelareorep exhibited synergy through immunological pathways, suggesting potential for broader therapeutic applications. The company aims to advance pelareorep in combination studies and is preparing for a pivotal phase 3 trial in metastatic breast cancer.
Oncolytics Biotech (NASDAQ: ONCY) announced that CEO Dr. Matt Coffey will participate in a panel discussion titled "Off-the-Shelf CAR T - solid tumors, myeloma, lymphoma" at the Canaccord Genuity Horizons in Oncology Virtual Conference.
Date: April 15, 2021, Time: 8:15 am ET.
Oncolytics is advancing its immuno-oncolytic virus, pelareorep, targeting various cancers. They are preparing for a Phase 3 registration study in metastatic breast cancer, exploring synergies with approved immuno-oncology therapies.
On April 5, 2021, Oncolytics Biotech announced a Key Opinion Leader (KOL) webinar for April 12, 2021, at 2:00 pm ET, focusing on AWARE-1 data concerning the immunotherapeutic effects of pelareorep in breast cancer and its synergy with CAR T cells. Key speakers include Dr. Aleix Prat from Hospital Clínic Barcelona and Dr. Richard Vile from the Mayo Clinic. The AWARE-1 study involves 38 patients and aims to evaluate pelareorep's efficacy. The company's management will also provide an update and be available for questions during the event.
Oncolytics Biotech (NASDAQ: ONCY) announced updated clinical data presentations from its AWARE-1 study on early-stage breast cancer and preclinical findings on pelareorep-based therapies. These will be shared at the AACR Annual Meeting on April 10-15, 2021. Key presentations include the AWARE-1 study's findings on pelareorep with atezolizumab and preclinical studies showing synergy with CDK4/6 inhibitors and talazoparib. The study's primary endpoint is CelTIL measurement, with 38 patients across five cohorts. Further details will be released post-abstract publication.
